• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

纠正剂可改变 F508del-CFTR 的碳酸氢盐通透性。

Correctors modify the bicarbonate permeability of F508del-CFTR.

机构信息

Istituto di Biofisica, Consiglio Nazionale delle Ricerche. Via De Marini, 6, 16149, Genova, Italy.

出版信息

Sci Rep. 2020 May 21;10(1):8440. doi: 10.1038/s41598-020-65287-4.

DOI:10.1038/s41598-020-65287-4
PMID:32439937
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7242338/
Abstract

One of the most common mutations in Cystic Fibrosis (CF) patients is the deletion of the amino acid phenylalanine at position 508. This mutation causes both the protein trafficking defect and an early degradation. Over time, small molecules, called correctors, capable of increasing the amount of mutated channel in the plasma membrane and causing an increase in its transport activity have been developed. This study shows that incubating in vitro cells permanently transfected with the mutated channel with the correctors VX809, VX661 and Corr4a, and the combination of VX809 and Corr4a, a recovery of anion transport activity is observed. Interestingly, the permeability of bicarbonate increases in the cells containing corrected p.F508del CFTR channels is greater than the increase of the halide permeability. These different increases of the permeability of bicarbonate and halides are consistent with the concept that the structural conformation of the pore of the corrector-rescued p.F508del channels would be different than the normal wild type CFTR protein.

摘要

在囊性纤维化 (CF) 患者中,最常见的突变之一是第 508 位氨基酸苯丙氨酸的缺失。这种突变导致蛋白转运缺陷和早期降解。随着时间的推移,已经开发出了一些称为校正剂的小分子,这些小分子能够增加突变通道在质膜中的数量,并增加其转运活性。本研究表明,用校正剂 VX809、VX661 和 Corr4a 以及 VX809 和 Corr4a 的组合孵育体外永久性转染突变通道的细胞,观察到阴离子转运活性的恢复。有趣的是,含有校正的 p.F508del CFTR 通道的细胞中碳酸氢盐通透性的增加大于卤化物通透性的增加。碳酸氢盐和卤化物通透性的这种不同增加与孔结构构象的概念一致,即校正剂拯救的 p.F508del 通道的结构构象不同于正常的野生型 CFTR 蛋白。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32ab/7242338/620959697a5d/41598_2020_65287_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32ab/7242338/620959697a5d/41598_2020_65287_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32ab/7242338/620959697a5d/41598_2020_65287_Fig2_HTML.jpg

相似文献

1
Correctors modify the bicarbonate permeability of F508del-CFTR.纠正剂可改变 F508del-CFTR 的碳酸氢盐通透性。
Sci Rep. 2020 May 21;10(1):8440. doi: 10.1038/s41598-020-65287-4.
2
Lumacaftor-rescued F508del-CFTR has a modified bicarbonate permeability.Lumacaftor 挽救的 F508del-CFTR 具有改良的碳酸氢盐通透性。
J Cyst Fibros. 2019 Sep;18(5):602-605. doi: 10.1016/j.jcf.2019.01.012. Epub 2019 Feb 7.
3
Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.解析突变 F508del-CFTR 更易受四种囊性纤维化校正剂作用的区域。
Int J Mol Sci. 2019 Nov 1;20(21):5463. doi: 10.3390/ijms20215463.
4
NBD2 Is Required for the Rescue of Mutant F508del CFTR by a Thiazole-Based Molecule: A Class II Corrector for the Multi-Drug Therapy of Cystic Fibrosis.NBD2 对于基于噻唑的分子对 F508del CFTR 突变体的挽救是必需的:囊性纤维化多药物治疗的 II 类矫正剂。
Biomolecules. 2021 Sep 28;11(10):1417. doi: 10.3390/biom11101417.
5
Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation.两种小分子可恢复具有主要致病突变的囊性纤维化跨膜传导调节因子亚群的稳定性。
J Biol Chem. 2017 Mar 3;292(9):3706-3719. doi: 10.1074/jbc.M116.751537. Epub 2017 Jan 13.
6
ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel.ORCAMBI 介导的囊性纤维化原代呼吸培养物黏液清除功能的恢复可通过精氨酸摄取、精氨酸酶抑制和促进一氧化氮信号转导至囊性纤维化跨膜电导调节子通道增强。
Mol Pharmacol. 2019 Oct;96(4):515-525. doi: 10.1124/mol.119.117143. Epub 2019 Aug 19.
7
F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.用于治疗囊性纤维化的F508del-囊性纤维化跨膜传导调节因子校正剂:专利综述
Expert Opin Ther Pat. 2015;25(9):991-1002. doi: 10.1517/13543776.2015.1045878. Epub 2015 May 15.
8
Characterization of the mechanism of action of RDR01752, a novel corrector of F508del-CFTR.RDR01752 作用机制的表征:一种新型 F508del-CFTR 校正剂。
Biochem Pharmacol. 2020 Oct;180:114133. doi: 10.1016/j.bcp.2020.114133. Epub 2020 Jul 3.
9
Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis.测量人原代肺细胞的功能反应,作为囊性纤维化个体化治疗的基础。
EBioMedicine. 2014 Dec 17;2(2):147-53. doi: 10.1016/j.ebiom.2014.12.005. eCollection 2015.
10
Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment.双校正剂治疗部分挽救 F508del-CFTR 的稳定性和运输缺陷。
Int J Mol Sci. 2021 May 17;22(10):5262. doi: 10.3390/ijms22105262.

引用本文的文献

1
Compound heterozygous variants in CFTR with potentially reducing ATP-binding ability identified in Chinese infertile brothers with isolated congenital bilateral absence of vas deferens.在中国不育兄弟的先天性双侧输精管缺如中鉴定出 CFTR 的复合杂合变体,具有潜在降低 ATP 结合能力。
Mol Genet Genomic Med. 2023 Nov;11(11):e2249. doi: 10.1002/mgg3.2249. Epub 2023 Jul 24.
2
Bicarbonate Effects on Antibacterial Immunity and Mucus Glycobiology in the Cystic Fibrosis Lung: A Review With Selected Experimental Observations.碳酸氢盐对囊性纤维化肺部抗菌免疫和黏液糖生物学的影响:一项包含选定实验观察结果的综述
Infect Microbes Dis. 2022 Sep;4(3):103-110. doi: 10.1097/im9.0000000000000101. Epub 2022 Aug 16.
3

本文引用的文献

1
Identification of GLPG/ABBV-2737, a Novel Class of Corrector, Which Exerts Functional Synergy With Other CFTR Modulators.新型校正剂GLPG/ABBV-2737的鉴定,其与其他CFTR调节剂发挥功能协同作用。
Front Pharmacol. 2019 May 9;10:514. doi: 10.3389/fphar.2019.00514. eCollection 2019.
2
The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy.Tezacaftor 和 ivacaftor 联合治疗囊性纤维化患者:囊性纤维化治疗的临床证据和未来前景。
Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619844424. doi: 10.1177/1753466619844424.
3
Organoid Technology and Its Role for Theratyping Applications in Cystic Fibrosis.
类器官技术及其在囊性纤维化治疗分型应用中的作用。
Children (Basel). 2022 Dec 20;10(1):4. doi: 10.3390/children10010004.
4
Modulator Combination Improves In Vitro the Microrheological Properties of the Airway Surface Liquid of Cystic Fibrosis Airway Epithelia.调节剂组合改善囊性纤维化气道上皮的气道表面液体的微流变学特性。
Int J Mol Sci. 2022 Sep 27;23(19):11396. doi: 10.3390/ijms231911396.
5
Advances in Preclinical In Vitro Models for the Translation of Precision Medicine for Cystic Fibrosis.用于囊性纤维化精准医学转化的临床前体外模型研究进展
J Pers Med. 2022 Aug 16;12(8):1321. doi: 10.3390/jpm12081321.
6
CFTR Modulators Restore Acidification of Autophago-Lysosomes and Bacterial Clearance in Cystic Fibrosis Macrophages.CFTR 调节剂恢复囊性纤维化巨噬细胞自噬溶酶体的酸化和细菌清除
Front Cell Infect Microbiol. 2022 Feb 16;12:819554. doi: 10.3389/fcimb.2022.819554. eCollection 2022.
7
Bicarbonate Transport in Cystic Fibrosis and Pancreatitis.囊性纤维化和胰腺炎中的碳酸氢盐转运。
Cells. 2021 Dec 24;11(1):54. doi: 10.3390/cells11010054.
8
Airway Surface Liquid pH Regulation in Airway Epithelium Current Understandings and Gaps in Knowledge.气道上皮中气道表面液体 pH 值的调节:当前的认识和知识缺口。
Int J Mol Sci. 2021 Mar 25;22(7):3384. doi: 10.3390/ijms22073384.
9
The Application of Bicarbonate Recovers the Chemical-Physical Properties of Airway Surface Liquid in Cystic Fibrosis Epithelia Models.碳酸氢盐的应用可恢复囊性纤维化上皮模型中气道表面液体的物理化学性质。
Biology (Basel). 2021 Mar 29;10(4):278. doi: 10.3390/biology10040278.
10
Choice of Differentiation Media Significantly Impacts Cell Lineage and Response to CFTR Modulators in Fully Differentiated Primary Cultures of Cystic Fibrosis Human Airway Epithelial Cells.分化培养基的选择对囊性纤维化气道上皮细胞的完全分化原代培养中细胞谱系和 CFTR 调节剂反应有显著影响。
Cells. 2020 Sep 21;9(9):2137. doi: 10.3390/cells9092137.
Small molecule-facilitated anion transporters in cells for a novel therapeutic approach to cystic fibrosis.
小分子促进细胞中的阴离子转运体用于囊性纤维化的新型治疗方法。
Br J Pharmacol. 2019 Jun;176(11):1764-1779. doi: 10.1111/bph.14649. Epub 2019 Apr 23.
4
Lumacaftor-rescued F508del-CFTR has a modified bicarbonate permeability.Lumacaftor 挽救的 F508del-CFTR 具有改良的碳酸氢盐通透性。
J Cyst Fibros. 2019 Sep;18(5):602-605. doi: 10.1016/j.jcf.2019.01.012. Epub 2019 Feb 7.
5
Structure-guided combination therapy to potently improve the function of mutant CFTRs.结构导向的联合治疗可显著改善突变型 CFTR 的功能。
Nat Med. 2018 Nov;24(11):1732-1742. doi: 10.1038/s41591-018-0200-x. Epub 2018 Oct 8.
6
Correctors of the Major Cystic Fibrosis Mutant Interact through Membrane-Spanning Domains.主要囊性纤维化突变体的校正因子通过跨膜结构域相互作用。
Mol Pharmacol. 2018 Jun;93(6):612-618. doi: 10.1124/mol.118.111799. Epub 2018 Apr 4.
7
Orkambi® and amplifier co-therapy improves function from a rare mutation in gene-edited cells and patient tissue.奥加替尼与增效剂联合治疗可改善经基因编辑细胞和患者组织中罕见突变的功能。
EMBO Mol Med. 2017 Sep;9(9):1224-1243. doi: 10.15252/emmm.201607137.
8
Molecular Structure of the Human CFTR Ion Channel.人 CFTR 离子通道的分子结构。
Cell. 2017 Mar 23;169(1):85-95.e8. doi: 10.1016/j.cell.2017.02.024.
9
Role of CFTR in epithelial physiology.囊性纤维化跨膜传导调节因子在上皮生理学中的作用。
Cell Mol Life Sci. 2017 Jan;74(1):93-115. doi: 10.1007/s00018-016-2391-y. Epub 2016 Oct 6.
10
Cystic fibrosis: a clinical view.囊性纤维化:临床视角
Cell Mol Life Sci. 2017 Jan;74(1):129-140. doi: 10.1007/s00018-016-2393-9. Epub 2016 Oct 5.